Summary & Overview
HCPCS J9351: Topotecan Injection, 0.1 mg
HCPCS Level II code J9351 denotes a unit of topotecan injectable therapy (0.1 mg) used in oncology care. As a drug-specific HCPCS Level II code, J9351 enables itemized reporting and reimbursement for administered topotecan across hospital outpatient, ambulatory infusion, and oncology clinic settings. Nationally, precise HCPCS reporting for cytotoxic agents like topotecan affects claim adjudication, physician and facility billing consistency, and aggregated drug utilization monitoring.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical purpose and service context, typical sites of service, and what to expect when this code appears on claims. The publication summarizes benchmark concepts and payer coverage considerations, highlights common modifier usage (listed separately), and provides clinical context for how J9351 maps to inpatient/outpatient chemotherapy delivery. Where specific payer policy details or utilization benchmarks are not provided in the input, the document indicates that the data are not available.
Billing Code Overview
HCPCS Level II code J9351 represents an injection of topotecan, dosed at 0.1 mg per unit. This code is used to report administration of the chemotherapeutic agent topotecan, commonly delivered via intravenous injection for oncology indications.
Service type: Chemotherapy drug administration (injectable antineoplastic agent)
Typical site of service: Hospital outpatient infusion center, oncology clinic, or ambulatory infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old female with recurrent epithelial ovarian carcinoma receives intravenous chemotherapy with topotecan. The oncology clinic schedules a cycle-based infusion visit where a registered nurse verifies patient identity, chemotherapy orders, and pre-medications. A physician or advanced practice provider documents the indication, regimen, dose in milligrams, and consent. Pharmacy compounds J9351 as topotecan 0.1 mg vials and performs final verification and labeling. At the outpatient infusion suite, nursing performs baseline vital signs, confirms laboratory results (complete blood count and renal function), administers antiemetics if ordered, and starts intravenous access. The topotecan injection is administered per protocol, patient is observed for infusion reactions and tolerated side effects, and post-infusion instructions are provided. Billing captures J9351 per 0.1 mg unit with appropriate diagnosis pointer(s) and any applicable modifier(s). Typical site of service is an outpatient infusion center or hospital outpatient department. Typical patient scenario includes patients with recurrent ovarian, small cell lung, or cervical cancers receiving single-agent topotecan for palliation or disease control.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/not administered to any patient |